The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues

Rossi, Roberta; Massironi, Sara

doi:10.3390/jcm11133794

Cited by 26 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Continuously increasing ASIR of GEP-NEN over the last decades were reported worldwide. [4][5][6]16,18,22 NEN incidence rates varied according to gender and ethnicity, geographic region, and tumor site. 1,6,22 Few studies investigated NEN in Germany 29 focusing either on NETs in general or on one selected GEP site.…”

Section: Discussionmentioning

confidence: 99%

“…Beyond other, these consisted of a change in consent on malignancy of specific histologic codes ('behavior code' change) and the inclusion of new histologic codes, for example, the functioning pancreatic neuroendocrine tumors (PanNETs), finally implemented in the first revision of the International Classification of Diseases for Oncology (ICD-O3). 14 Previous epidemiological research on GEP-NEN reported continuously rising incidence rates for the last decades, 6,[15][16][17][18] predominantly for countries of Western Europe, North America, and from Japan. The United States, to give just one example, experienced a strong increase of GEP-NEN rates, which rose 3.6-fold between 1973 and 2007.…”

Section: Introductionmentioning

confidence: 99%

“…Previous epidemiological research on GEP‐NEN reported continuously rising incidence rates for the last decades, 6,15–18 predominantly for countries of Western Europe, North America, and from Japan. The United States, to give just one example, experienced a strong increase of GEP‐NEN rates, which rose 3.6‐fold between 1973 and 2007 15 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Site‐specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany

Grundmann,

Voigtländer,

Hakimhashemi

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

IntroductionNeuroendocrine neoplasms (NEN) are rare and heterogeneous epithelial tumors, occurring throughout the body. For gastroenteropancreatic (GEP)‐NEN, rising incidence rates were reported for the last decades, with underlying causes remaining largely unexplained. We evaluated NEN trends stratifying by their histologic subtypes.MethodsIncident cases of GEP‐NEN diagnosed between 2005 and 2019 were retrieved from the prospective, population‐based Bavarian Cancer Registry. GEP‐NEN were divided in their histologic subtypes, that is, neuroendocrine tumors (NET) G1, NET G2/G3, other NET versus small‐cell neuroendocrine carcinoma (NEC), large‐cell NEC, and other NEC. We calculated annual age‐standardized incidence rates (ASIRs) per 100,000 persons for the total of GEP‐NEN, NEN histologic subtypes, and tumor sites. We used an annual percentage change (APC) approach including a joinpoint analysis to investigate NEN incidence trends.ResultsASIR of GEP‐NEN rose from 2.2 in 2005 to 4.8 in 2019, characterized by a significant increase until 2012 (APC 2005–2012: 10.1%), followed by modest rise (APC 2012–2019: 1.5%). In the last decade, this increase was mainly driven by the rise of NET G1 and G2/G3, while incidence for NEC declined. Over the study period, ASIR increased significantly for all GEP‐sites except the colon. APCs were largest for the stomach, the appendix, the pancreas, and the rectum.ConclusionsThis study found a significant increase in the incidence of GEP‐NET. Though this development may partially be attributable to the increased use of advanced detection techniques and changes in NEN classification, further research should also focus on the identification of NEN risk factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Site‐specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany

Grundmann,

Voigtländer,

Hakimhashemi

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…The overall incidence of NENs has continued to increase over the past 40 years, and the incidence of pNETs has also increased ( 8 – 10 ). pNETs are heterogeneous tumors of the neuroendocrine system originating from islet cells of the pancreas ( 11 ).…”

Section: Discussionmentioning

confidence: 99%

“…pNENs are rare pancreatic tumors, the incidence of which has increased significantly in recent years. With the advancement of inspection technology and the popularization of health examinations, the clinical detection rate of pNENs has also shown an upward trend ( 7 , 8 ). More than half of the pNENs are G1 pancreatic NETs (G1 pNETs).…”

Section: Introductionmentioning

confidence: 99%

The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database

Qiu

Liu

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPancreatic neuroendocrine tumors (pNETs) are rare neuroendocrine neoplasms (NENs) for which little is known about their clinical features, treatment options, and survival prognosis. The purpose of this study is to evaluate the risk factors affecting the overall survival (OS) and cancer-specific survival (CSS) in patients with grade 1 pNETs (G1 pNETs) and to provide a new theoretical basis for clinical diagnosis and treatment.MethodsA retrospective analysis of individuals with G1 pNETs registered in the Surveillance, Epidemiology, End Results (SEER) database was performed. Risk factors affecting OS and CSS were analyzed using Kaplan-Meier analysis, Cox proportional hazards model, and Fine-Gray competing-risk model.ResultsA total of 751 patients were included, most of whom were white (77.2%) women (53.9%) under the age of 60 years (54.9%), of whom 66 died of pNETs (8.78%) and 34 died of other causes (4.52%). Patients who were older than 60 years at diagnosis (hazard ratio [HR] = 1.866, 95% confidence interval [CI]: 1.242-2.805) had worse OS. And stage in the regional extent (HR = 1.777, 95% CI: 1.006-3.137) or distance extent (HR = 4.540, 95% CI: 2.439-8.453) had worse OS. Patients who delayed treatment after diagnosis had shorter CSS (delayed treatment < 1 month: HR = 1.933, 95% CI: 0.863-4.333; delayed treatment ≥ 1 month: HR = 2.208; 95% CI:1.047-4.654). Patients with lymph node metastasis (HR = 1.989, 95% CI: 1.137-3.479) or distant metastasis (HR = 5.625, 95% CI: 1.892-16.726) had worse CSS. Acceptance of surgery can significantly improve the patient’s OS and CSS. OS (partial pancreatectomy [PP]: HR = 0.350, 95% CI: 0.182-0.672; pancreatectomy and duodenectomy [PD]: HR = 0.426, 95% CI: 0.222-0.815; total pancreatectomy [TP]: HR = 0.495, 95% CI: 0.193-1.267). CSS(PP: HR = 0.148, 95% CI: 0.0054-0.401; PD: HR = 0.332, 95% CI: 0.150-0.730; TP: HR = 0.69, 95% CI: 0.254-1.872).ConclusionAge and stage were identified as independent risk factors for OS. Delayed treatment, N stage and M stage were independent risk factors for CSS. Only surgery was identified as independent protective factors for OS and CSS.

show abstract

Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan

Chen,

Bai,

Cheng

et al. 2024

Oncol Ther

View full text Add to dashboard Cite

The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues

Abstract: Neuroendocrine neoplasms (NENs) include a heterogeneous group of tumors derived from neuroendocrine cells, most commonly arising from the gastro-entero-pancreatic (GEP) and bronchopulmonary tracts [...]

Cited by 26 publications

References 23 publications

Site‐specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany

Site‐specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany

The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database

Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan

Contact Info

Product

Resources

About